Showing 4111-4120 of 5994 results for "".
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- Algae May Enhance Skin Regeneration and Wound Healing: Studyhttps://practicaldermatology.com/news/algae-may-enhance-skin-regeneration-and-wound-healing-study/2461496/Euglena gracilis may enhance skin regeneration to speed wound healing, according to new research. Investigators developed a system based on microvesicles that bud from the cell surface of Euglena gracilis, a freshwater single-celled green algae, and conta
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- FDA Grants Fast Track Designation for Union’s Oral Orismilast for Moderate to Severe HShttps://practicaldermatology.com/news/fda-grants-fast-track-designation-for-unions-oral-orismilast-for-the-treatment-of-moderate-to-severe-hs/2461493/The US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS). The FDA's Fast Track designation is intended to facilitate the development and review of drug candidates that treat
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Can Harnessing a Tumor’s Power Help Heal Diabetic Foot Ulcers?https://practicaldermatology.com/news/can-harnessing-a-tumors-power-help-heal-diabetic-foot-ulcers/2461480/Scientists may have found a way to train healthy immune cells to accelerate diabetic wound healing. The findings appear in EMBO Molecular Medicine. Diabetic foot ulcers result in
- Apyx Medical Launches #ThisIsMe Campaign for Renuvionhttps://practicaldermatology.com/news/apyx-medical-launches-thisisme-campaign-for-renuvion/2461478/Apyx Medical Corporation is rolling out its first-ever direct-to-consumer brand campaign for Renuvion, a proprietary helium plasma and radiofrequency technology. The #ThisIsMe campaign is aimed at U.S. consumers who are interested in a minimally invas
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat